Paraproteinemic neuropathies
https://doi.org/10.30629/2658-7947-2024-29-2-4-16
Abstract
Paraproteinemic polyneuropathies (PPN) occur generally infrequently and arise from diseases, associated with formation and accumulation of a pathological protein, commonly known as paraprotein, which is typically an immunoglobulin or its free light chain. Such diseases include the following: monoclonal gammopathy of undetermined significance, multiple myeloma, Waldenström’s macroglobulinemia, AL amyloidosis, POEMS syndrome, etc. Diagnosis of PPN is challenging due to nonspecific, indistinct or atypical clinical manifestation, and it is necessary to apply specialized laboratory methods, including immunochemical analysis of blood and urine. Moreover, medications can cause symptoms of polyneuropathy themselves. Thus, it is important to suspect the first symptoms of the disease in time, determine the mechanism of damage to nerve fibers, carry out differential diagnosis and initiate therapy targeting the suppression of pathological protein synthesis.
About the Authors
O. E. Zinovyeva
The Department of Nervous Diseases and Neurosurgery of the Institute of Clinical Medicine of the I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Moscow
D. K. Novikov
The Department of Nervous Diseases and Neurosurgery of the Institute of Clinical Medicine of the I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Moscow
N. Z. Ochil-zoda
The Department of Nervous Diseases and Neurosurgery of the Institute of Clinical Medicine of the I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Moscow
V. V. Rameev
The Department of Internal, Occupational Diseases and Rheumatology of the Institute of Clinical Medicine of the I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Moscow
References
1. Lange D.J., Robinson-Papp J. Immune-mediated neuropathies. UpToDate. 2021. https://www.uptodate.com/contents/immune-mediated-neuropathies
2. Khwaja J., D’Sa S., Minnema M.C., Kersten M.J., Wechalekar A., Vos J.M.I. IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica. 2022;107:2037– 2050. https://doi.org/10.3324/HAEMATOL.2022.280953
3. Schnitzler L., Schubert B., Boasson M., Gardais J., Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM: maladie de Waldenström? 2ème présentation. Bull Soc Fr Dermatol Syphil. 1974;81:363.
4. Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program. 2020:380– 388. https://doi.org/10.1182/HEMATOLOGY.2020000122
5. Lysenko L.V., Rameev V.V., Androsova T.V. Monoclonal gammopathy of renal significance (MGRS) at the current state: Terminology, diagnosis and treatment. Therapeutic Archive (Terapevticheskiy arkhiv). 2020;92(6):15–22. (In Russ.). https://doi.org/10.26442/00403660.2020.06.000666
6. Mrykhin N.N., Lysenko L.V., Chebotareva N.V., Rameev V.V., Androsova T.V., Roshchupkina S.V., Gitel E.P., Kogarko I.N., Maryina S.A. The detection rate and variants of monoclonal gammopathy among patients in a multidisciplinary therapeutic hospital. The Doctor (Vrach). 2019;30(2):54–59. (In Russ.). https://doi.org/10.29296/25877305-2019-02-11
7. Kaseb H., Annamaraju P., Babiker H.M. Monoclonal Gammopathy of Undetermined Significance. StatPearls. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507880/
8. Carrère F., Plasse F., Pasini S., Vignon G., Mottaz P., Bonnin A., Augereau P.F., Aucher P., Lellouche F. Monoclonal gammopathy of undetermined significance (MGUS): interpretative shades of analysis and sometimes serious clinical consequences. Ann Biol Clin (Paris). 2019;77:245–254. https://doi.org/10.1684/ABC.2019.1440
9. Lomas O.C., Mouhieddine T.H., Tahri S., Ghobrial I.M. Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. Cancers (Basel). 2020;12:1–16. https://doi.org/10.3390/CANCERS12061554
10. Visentin A., Pravato S., Castellani F., Campagnolo M., Angotzi F., Cavarretta C.A., Cellini A., Ruocco V., Salvalaggio A., Tedeschi A., Trentin L., Briani C. From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. Cancers (Basel). 2020;14. https://doi.org/10.3390/CANCERS14061562
11. Kastritis E., Leblond V., Dimopoulos M.A., Kimby E., Staber P., Kersten M.J., Tedeschi A., Buske C. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv41–iv50. https://doi.org/10.1093/ANNONC/MDY146
12. Briani C., Ferrari S., Campagnolo M., Tagliapietra M., Castellani F., Salvalaggio A., Mariotto S., Visentin A., Cavallaro T. Mechanisms of Nerve Damage in Neuropathies Associated with Hematological Diseases: Lesson from Nerve Biopsies. Brain Sci. 2021;11:1–14. https://doi.org/10.3390/BRAINSCI11020132
13. Cingam S., Sidana S. Differential Diagnosis of Waldenström’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice. Blood Lymphat Cancer. 2022;12:107. https://doi.org/10.2147/BLCTT.S259860
14. Mena-Vázquez N., Cabezudo-García P., Fuego Varela C., Manrique-Arija S., Fernandez-Nebro A. Efficacy and safety of Rituximab in vasculitic neuropathy: a systematic review of the literature. Reumatol Clin. 2019;15:173–178. https://doi.org/10.1016/J.REUMA.2018.10.007
15. Le Cann M., Bouhour F., Viala K., Simon L., Tard C., Rossi C., Morel G., Lagrange E., Magy L., Créange A., Michaud M., Franques J., Echaniz-Laguna A., Antoine J.C., Baron M., Arnulf B., Puma A., Delmont E., Maisonobe T., Leblond V., Roos-Weil D. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies. Blood. 2020;136:2428–2436. https://doi.org/10.1182/BLOOD.2020007092
16. Hobbs M., Fonder A., L. Hwa Y. Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management. J Adv Pract Oncol. 2020;11:381. https://doi.org/10.6004/JAD-PRO.2020.11.4.5
17. Fox T.A., Lunn M., Wechalekar A., Bomanji J., Wan S., D’Sa S. [18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström’s Macroglobulinemia. Haematologica. 2018;103:e322. https://doi.org/10.3324/HAEMATOL.2017.184515
18. Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96:872–888. https://doi.org/10.1002/AJH.26240
19. Kim Y.R. Update on the POEMS syndrome. Blood Res. 2022;57:27. https://doi.org/10.5045/BR.2022.2022001
20. Isshiki Y., Oshima M., Mimura N., Kayamori K., Miyamoto-Nagai Y., Seki M., Nakajima-Takagi Y., Kanamori T., Iwamoto E., Muto T., Tsukamoto S., Takeda Y., Ohwada C., Misawa S., Ikeda J.I., Sanada M., Kuwabara S., Suzuki Y., Sakaida E., Nakaseko C., Iwama A. Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis. JCI Insight. 2022;7. https://doi.org/10.1172/JCI.INSIGHT.151482
21. Wang Y., Huang L.B., Shi Y.H., Fu H., Xu Z., Zheng G.Q., Wang Y. Characteristics of 1946 cases of POEMS syndrome in Chinese subjects: A literature-based study. Front Immunol. 2019;10:450504. https://doi.org/10.3389/FIMMU.2019.01428/BIBTEX
22. Odin V.I., Polyakov A.S., Kovalev A.V., Bondarchuk S.V., TyrenkoV.V., Mykhailov A.M., Bogovskaya T.Yu. Paraneoplastic endocrinopathy in Castleman disease and POEMS syndrome. Oncohematology (Onkogematologiya). 2020;15:67–79. (In Russ.). https://doi.org/10.17650/1818-8346-2020-15-3-67-79
23. Butzmann A., Kumar J., Sridhar K., Gollapudi S., Ohgami R.S. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease. Biology (Basel). 2021;10. https://doi.org/10.3390/BIOLOGY10040251
24. Carbone A., Borok M., Damania B., Gloghini A., Polizzotto M.N., Jayanthan R.K., Fajgenbaum D.C., Bower M. Castleman disease. Nat Rev Dis Primers. 2021;7:84. https://doi.org/10.1038/S41572-021-00317-7
25. Brown R., Ginsberg L. POEMS syndrome: clinical update. J Neurol. 2019;266:268. https://doi.org/10.1007/S00415-018-9110-6
26. Laubach J.P. Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis. UpToDate. 2023. https://www.uptodate.com/contents/multiple-myeloma-clinical-features-laboratory-manifestations-and-diagnosis
27. Abeykoon J.P., Tawfiq R.K., Kumar S., Ansell S.M. Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond. Fac Rev. 2022;11. https://doi.org/10.12703/R/11-34
28. Kozlovskaya L.V., Rameev V.V., Kogarko I.N., Gordovskaya N.B., Chebotareva N.V., Androsova T.V., Roshchupkina S.V., Mrykhin N.N., Russkikh A.V., Loshkareva O.A., Sidorova E.I. Renal lesions associated with monoclonal gammopathies of undetermined significance: clinical forms, mechanisms of development, approaches to treatment. Clinical Medicine (Russian Journal). 2016;94(12):892–901. (In Russ.). doi: 10.18821/0023-2149-2016-94-12-892-901
29. Derman B., Castillo J.J., Sarosiek S., Beksac M. When a Monoclonal Gammopathy Is Not Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2022;42:655–664. https://doi.org/10.1200/EDBK_349643
30. Kaedbey R., Forward N., Sehn L.H., Shafey M., Doucette S., Chen C.I. A Canadian Perspective on the Treatment of Walden-ström Macroglobulinemia. Curr Oncol. 2022;29:7122–7139. https://doi.org/10.3390/CURRONCOL29100560
31. Gertz M.A. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96:258–269. https://doi.org/10.1002/AJH.26082
32. Treon S.P., Xu L., Guerrera M.L., Jimenez C., Hunter Z.R., Liu X., Demos M., Gustine J., Chan G., Munshi M., Tsakmaklis N., Chen J.G., Kofides A., Sklavenitis-Pistofidis R., Bustoros M., Keezer A., Meid K., Patterson C.J., Sacco A., Roccaro A., Branagan A.R., Yang G., Ghobrial I.M., Castillo J.J. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020;38:1198–1208. https://doi.org/10.1200/JCO.19.02314
33. Sammartano V., Cerase A., Venanzi V., Mazzei M.A., Vangone B.E., Gentili F., Chiarotti I., Bocchia M., Gozzetti A. Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance. Front Oncol. 2022;12. https://doi.org/10.3389/FONC.2022.934240
34. LeBlanc R., Bergstrom D.J., Côté J., Kotb R., Louzada M.L., Sutherland H.J. Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk. 2022;22:e41–e56. https://doi.org/10.1016/J.CLML.2021.07.028
35. Dispenzieri A., Vincent R., Rebecca F.C. POEMS syndrome. UpToDate. 2023. https://www.uptodate.com/contents/poems-syndrome
36. Yang P., Qu Y., Wang M., Chu B., Chen W., Zheng Y., Niu T., Qian Z. Pathogenesis and treatment of multiple myeloma. Med-Comm (Beijing). 2022;3. https://doi.org/10.1002/MCO2.146
37. Ihne S., Morbach C., Sommer C., Geier A., Knop S., Störk S. Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. Dtsch Arztebl Int. 2020;117:159–166. https://doi.org/10.3238/ARZTEBL.2020.0159
38. Zinovyeva O.E., Safiulina E.I., Shcheglova N.S., Surnina Z.V., Nosovskiy A.M. Evaluation of peripheral amyloid neuropathy. Neurology, Neuropsychiatry, Psychosomatics (Nevrologiya, neiropsikhiatriya, psikhosomatika). 2021;13(5):56–61. (In Russ.). https://doi.org/10.14412/2074-2711-2021-5-56-61
39. Adams D., Ando Y., Beirão J.M., Coelho T., Gertz M.A., Gillmore J.D., Hawkins P.N., Lousada I., Suhr O.B., Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268:2109. https://doi.org/10.1007/S00415-019-09688-0
40. Damy T., Adams D., Bridoux F., Grateau G., Planté-Bordeneuve V., Ghiron Y., Farrugia A., Pelcot F., Taieb C., Labeyrie C., Jaccard A., Georgin-Lavialle S. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29:165–174. https://doi.org/10.1080/13506129.2022.2035354
41. Rameev V.V., Kozlovskaya L.V., Rameeva A.S., Tao P.P., Moiseev S.V. Evolution and prognostic significance of heart involvement in patients with systemic AL-amyloidosis. Clin Pharmacol Ther (Klinicheskaya farmakologiya i terapiya). 2019;28(2):49–56. (In Russ.). https://doi.org/10.32756/0869-5490-2019-2-49-56.
42. Nikitin S.S., Bardakov S.N., Suponeva N.A., Zhirov I.V., Adyan T.A., Grishina D.A., Deev R.V. Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy. Neuromuscular Diseases (Nervnomyschechnye bolezni). 2021;11(3):12–36. (In Russ.). https://doi.org/10.17650/2222-8721-2021-11-3-12-36.
43. Zoccarato M., Grisold W., Grisold A., Poretto V., Boso F., Giometto B. Paraneoplastic Neuropathies: What’s New Since the 2004 Recommended Diagnostic Criteria. Front Neurol. 2021;12. https://doi.org/10.3389/FNEUR.2021.706169
44. Safiulina E.I., Zinovyeva O.E., Rameev V.V., Kozlovskaya-Lysenko L.V. Peripheral nervous system involvement in systemic amyloidosis. Neurology, neuropsychiatry, psychosomatics (Nevrologiya, neiropsikhiatriya, psikhosomatika). 2018;10(3):12–18. (In Russ.). https://doi.org/10.14412/2074-2711-2018-3-12-18
45. Gavriatopoulou M., Musto P., Caers J., Merlini G., Kastritis E., van de Donk N., Gay F., Hegenbart U., Hajek R., Zweegman S., Bruno B., Straka C., Dimopoulos M.A., Einsele H., Boccadoro M., Sonneveld P., Engelhardt M., Terpos E. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32:1883–1898. https://doi.org/10.1038/S41375-018-0209-7
46. Trukhin I.V., Schekochikhin D.Yu., Novikova N.A., Akselrod A.S., Syrkin A.L., Syrkina E.A., Grachev A.E., Gribanova O.E., Okhota V.K., Ryzhko V.V., Pershina E.S. Heart involvement in AL-amyloidosis. Current state of the issue. Annals of the Russian Academy of Medical Sciences (Vestnik Rossiiskoi akademii medetsinskikh nauk). 2019;74(5):307–316. (In Russ.). https://doi.org/10.15690/vramn1184
47. Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev S.V., Blagova O.V., Bogdanov E.I., Gendlin G.E., Grishina D.A., Gudkova A.Ya., Zakharova E.V., Zinovyeva O.E., Moiseeva O.M., Nikitin S.S., Parfenov V.A., Suponeva N.A., Tereshenko S.N. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Clin Pharmacol Therapy (Klinicheskaya farmakologiya i terapiya). 2020;29(1):13–24. (In Russ.). https://doi.org/10.32756/0869-5490-2020-1-13-24.
48. Treon S.P., Soumerai J.D., Branagan A.R., Hunter Z.R., Patterson C.J., Ioakimidis L., Briccetti F.M., Pasmantier M., Zimbler H., Cooper R.B., Moore M., Hill J., Rauch A., Garbo L., Chu L., Chua C., Nantel S.H., Lovett D.R., Boedeker H., Sonneborn H., Howard J., Musto P., Ciccarelli B.T., Hatjiharissi E., Anderson K.C. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112:4452–4457. https://doi.org/10.1182/BLOOD-2008-04-150854
49. Burgess J., Ferdousi M., Gosal D., Boon C., Matsumoto K., Marshall A., Mak T., Marshall A., Frank B., Malik R.A., Alam U. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncol Ther. 2021;9:385. https://doi.org/10.1007/S40487-021-00168-Y
50. Kakimoto Y., Hoshino M., Hashimoto M., Hiraizumi M., Shimizu K., Chou T. Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance. Internal Medicine. 2022;61:1337. https://doi.org/10.2169/INTERNALMEDICINE.7768-21
51. Imtiaz H., Khan M., Ehsan H., Wahab A., Rafae A., Khan A.Y., Jamil A., Sana M.K., Jamal A., Ali T.J., Ansar I., Khan M.M., Khouri J., Anwer F. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. Onco Targets Ther. 2021;14:4941. https://doi.org/10.2147/OTT.S317570
52. Zajaczkowską R., Kocot-Kępska M., Leppert W., Wrzosek A., Mika J., Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019;20. https://doi.org/10.3390/IJMS20061451
53. Colvin L.A. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain. 2019;160:S1. https://doi.org/10.1097/J.PAIN.0000000000001540
54. Semochkin S.V., Solovyev M.V., Mendeleeva L.P. Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Oncohematology (Onkogematologiya). 2022;17(2):141–50. (In Russ.). https://doi.org/10.32756/0869-5490-2020-1-13-24.
55. Chen Y., Tang X. Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association with Concomitant Diseases: Identification and Management. Front Immunol. 2022;13. https://doi.org/10.3389/FIMMU.2022.890142
56. Rajabally Y.A., Attarian S., Delmont E. Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy. J Inflamm Res. 2020;13:543. https://doi.org/10.2147/JIR.S224781
Review
For citations:
Zinovyeva O.E., Novikov D.K., Ochil-zoda N.Z., Rameev V.V. Paraproteinemic neuropathies. Russian neurological journal. 2024;29(2):4-16. (In Russ.) https://doi.org/10.30629/2658-7947-2024-29-2-4-16
Views:
589
Email this article 